Disclosure of the salary of the employees of 10 billion revenue pharmaceutical enterprises, more than 170000 yuan in 5 companies

[pharmaceutical Station industry trends] it is reported that in 2018, of the 35 A-share pharmaceutical listed companies with revenues of more than 10 billion, 10 companies' employees' per capita salary is more than 150000 yuan, including Mindray medical, Sinopharm, Tianshili, Intech group, Baiyunshan, Yunnan Baiyao, Huadong pharmaceutical, Tongrentang, China resources Sanjiu and Haizheng pharmaceutical Among them, the average salary of employees in five pharmaceutical enterprises is more than 170000 yuan In 2018, the income of Mindray medical increased by 23% to 13.8 billion yuan, and the net profit increased by 44% to 3.7 billion yuan Mindray medical is the leader in the field of medical devices, and its fundamentals are developing well It mainly refers to the value promotion brought by the product intelligence and the market ceiling opened with it It is also reported that the total salary of 18 paid executives of Mindray medical in 2018 was 93.26 million yuan, of which the average salary of 3 independent directors was 180000 yuan The average salary of directors and supervisors is 5.18 million yuan / person, excluding the average salary of 3 independent directors of 6.18 million yuan / person Among them, there are four senior executives whose salary is more than 10 million yuan, chairman Li Xiting's salary last year was 17.323 million yuan, general manager Cheng Minghe's 16.3391 million yuan, executive deputy general manager Wu Hao's 10.1365 million yuan, and deputy general manager Li jaewen's 10.0128 million yuan The average salary of employees of Sinopharm is 223800 yuan Sinopharm released the quarterly report in 2019, realizing the operating revenue of 10.049 billion yuan, up 10.07% year on year; the net profit attributable to shareholders of listed companies is 286 million yuan, up 12.41% year on year; the net profit attributable to shareholders of listed companies is 285 million yuan, up 12.45% year on year; Basic earnings per share is 0.12 yuan In the quarter of 2019, the average per capita salary of tisley's employees was RMB 1.948 million In the quarter of 2019, tisley realized an operating income of RMB 4.571 billion, an increase of 15.66% year on year; the net profit attributable to shareholders of listed companies was RMB 448 million, an increase of 20.64% year on year; the net profit attributable to shareholders of listed companies after deducting non honest profit and loss was RMB 396 million, 10.28% year on year; and the basic earnings per share was RMB 0.2971 According to the announcement, in the quarter of 2019, the operating revenue increased by 15.66% over the same period of last year Among them, the income of pharmaceutical industry increased by 10.38%, and the income of pharmaceutical business increased by 17.59% In addition, in the quarter of 2019, the net cash flow from operating activities increased by 70.58% compared with the same period of last year, mainly due to the decrease of the actual taxes paid by the company in the reporting period compared with the same period of last year During the reporting period, Intech group achieved revenue of 5682323196.02 yuan, a year-on-year increase of 10.93%; net profit attributable to shareholders of listed companies was 30487825.87 yuan, a year-on-year increase of 32.09% As of the end of the reporting period, the net assets of Intech group attributable to shareholders of the listed company were 963067234.86 yuan, an increase of 11.61% over the end of the previous year; the net cash flow from operating activities was -1094477095.05 yuan Baiyunshan employee's per capita salary is RMB 179200 In the quarter of 2019, the company's operating revenue (the same below) is RMB 18.055 billion, a year-on-year increase of 161.32%, the net profit attributable to the company's shareholders is RMB 1.407 billion, a year-on-year increase of 55.42%, the basic earnings per share is RMB 0.865, and the weighted average return on net assets is 6.28% During the reporting period, Guangzhou Pharmaceutical Co., Ltd and Guangzhou Wanglaoji Pharmaceutical Co., Ltd were incorporated into the consolidation scope of the company, while the two companies mentioned above were joint ventures of the company in the same period last year, which increased the amount of the statement project in the reporting period by 9.402 billion yuan.